Johnson Matthey PLC (LON:JMAT – Get Free Report) insider Liam Condon bought 21 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was bought at an average cost of GBX 1,598 ($21.11) per share, for a total transaction of £335.58 ($443.30).
Johnson Matthey Trading Down 8.5 %
JMAT stock opened at GBX 1,470 ($19.42) on Friday. The company has a market capitalization of £2.59 billion, a PE ratio of 2,534.48, a price-to-earnings-growth ratio of 49,242.50 and a beta of 0.95. Johnson Matthey PLC has a one year low of GBX 1,428.50 ($18.87) and a one year high of GBX 1,917.07 ($25.32). The company’s 50 day moving average price is GBX 1,613.66 and its two-hundred day moving average price is GBX 1,685.55. The company has a debt-to-equity ratio of 63.15, a quick ratio of 0.76 and a current ratio of 1.45.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 2,400 ($31.70) target price on shares of Johnson Matthey in a research note on Monday, June 24th. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 1,800 ($23.78) target price on shares of Johnson Matthey in a research note on Tuesday, June 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of GBX 1,993.33 ($26.33).
About Johnson Matthey
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
See Also
- Five stocks we like better than Johnson Matthey
- How to Read Stock Charts for Beginners
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What Investors Need to Know to Beat the Market
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Stock Splits, Do They Really Impact Investors?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.
